Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan's assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/03/17 | $150,000,000 | Series A |
F2 Ventures MPM Capital  | undisclosed |
| 06/04/20 | $98,500,000 | Series B |
F2 Ventures MPM Capital | undisclosed |
